
Nippon Shinyaku Co., Ltd.
NPPNY
Updated: 23/09/2026, 06:32:51
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
No summaries found.
- Share price
- $5.46
- Market cap
- $1.47B
- Exchange
- OTC
- Currency
- USD
- CEO
- Toru Nakai
- Employees
- 2,309
- IPO date
- 16/11/2016
- Beta
- -0.324
- Last dividend
- $0.00
- Day range
- $5.46 – $5.75
- 52-week range
- $5.03 – $15.21
- 1-day performance
- 0.00%
- 1-year performance
- 8.60%
- Current drawdown (1Y)
- -64.10%
- CIK
- N/A
- CUSIP
- 65461U108
- ISIN
- US65461U1088
- Created
- 07/12/2025, 05:29:37
- Last update
- 23/09/2026, 06:32:51
Track Nippon Shinyaku Co., Ltd. with an AI analyst
See which prediction-market events move NPPNY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.